INOVIQ (ASX:IIQ) has scrapped its 1,200-sample EXO-OC validation study after biobank quality issues, but the ovarian cancer algorithm just improved.
01
Stocks in Spotlight
View all →-
Financials · Growth Stocks Powerhouse Ventures (ASX:PVL) US$50m Partner Commitment Puts CIO Fund Re-Rate in Focus June 26, 2026 -
Growth Stocks WiseTech Global (ASX:WTC) Why the A$30 Sell-Off Could Be a Long-Term Opportunity June 23, 2026 -
